title: Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Kast
authors.forename: Eric L
authors.initials: EL
authors.lastname: Altschuler
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D054316:Biomarkers, Pharmacological / Q000097:blood; D003424:Crohn Disease / Q000139:chemically induced; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000097:blood*
chemical_list: D000911:Antibodies, Monoclonal; D054316:Biomarkers, Pharmacological; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept